Maze House Medical

Executive Summary

Maze House Medical is a UK-based contract research organization (CRO) specializing in medical writing services for clinical trials, regulatory submissions, and publications. Founded in 2011, the company offers a comprehensive suite of services including clinical study reports, protocols, safety narratives, investigator brochures, and manuscript preparation. With the global clinical trial market expanding and increasing regulatory demands for high-quality documentation, Maze House is well-positioned to capture growing demand from pharmaceutical, biotech, and medical device clients. The company's focus on quality control and advisory board support differentiates it from competitors. While not a high-growth drug developer, its recurring revenue model and low capital intensity provide stable cash flow. Expansion into new geographies or therapeutic areas could drive growth, but the company remains small and privately held, limiting visibility.

Upcoming Catalysts (preview)

• Q4 2026Major Contract Win with Top-20 Pharma30% success
• Q2 2027Expansion into EU Market via New Office20% success
• Q3 2026Launch of AI-Powered Medical Writing Platform25% success